Apogee Therapeutics, Inc.
APGE
Rang in Aktien
#2354
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aktienkurs
$135.07
Zuletzt synchronisiert: 2026-09-04
Marktkapitalisierung
$8.36B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
144.91%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategorie
Healthcare
EPS für Apogee Therapeutics, Inc. (APGE)
EPS zum June 2026 TTM: $-4.34
Laut den aktuellen Finanzberichten und dem Aktienkurs von Apogee Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-4.34. Am Ende des Jahres 2023 betrug das EPS $-1.66 eine Steigerung gegenüber dem EPS von 2022, das $-0.79 betrug.
EPS-Verlauf von Apogee Therapeutics, Inc. von 2022 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
